Tag: GlobeNewswire

Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end

ZUG, Switzerland, October 7, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced that Riad Sherif, M.D., Chief Executive Officer of Oculis, will present at Eyecelerator @ AAO 2026 on October 8, 2026, and that the Company will sponsor the Neuro-Ophthalmology Subspecialty Day at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting on October 9, 2026, in New Orleans, Louisiana. 

At Eyecelerator @ AAO 2026, Dr. Sherif will present Licaminlimab, a novel topical anti-TNFα candidate being developed with a genotype-based precision medicine approach for TNFR1-mediated dry eye disease, in the PREDICT-1 registrational symptoms trial on track for topline readout around year-end.

Oculis will also partner with the Neuro-Ophthalmology Subspecialty Day, reflecting the Company’s commitment to advancing neuro-ophthalmology through scientific exchange, education, and collaboration with experts in research, clinical practice, and emerging technologies to improve care for patients with neuro-ophthalmic diseases. 

Riad Sherif, M.D., Chief Executive Officer of Oculis, said: “AAO provides a valuable opportunity to engage with the broader ophthalmology and neuro-ophthalmology communities and discuss how innovation can address persistent unmet needs in both fields. The upcoming topline results from PREDICT-1 have the potential to further advance our aim of bringing precision medicine to TNFR1-mediated dry eye disease, while the continued progress of Privosegtor reflects our commitment to transforming outcomes for patients facing neuro-ophthalmic diseases. Together, these programs illustrate Oculis’ strategy of pursuing highly differentiated therapies with the potential to redefine standards of care.”

Details of Oculis’ presentation at Eyecelerator @ AAO 2026 are as follows: 

Session: Anterior segment showcase
Date / Time: October 8, 1:24 PM CDT
Room: 243-245
Presenter: Riad Sherif, M.D., Chief Executive Officer

– Ends –

About Licaminlimab 

Licaminlimab is an anti-TNFα eye drop candidate being developed with a single chain antibody fragment (scFv) technology specifically developed to treat ocular inflammatory diseases. The dual anti-inflammatory and anti-necrotic mechanism of action of TNFα inhibition is well established in inflammatory disorders, where systemic use of TNFα inhibitors has led to marked improvements in disease management and treatment outcomes. In Phase 2 trials, Licaminlimab has shown a positive treatment effect on both the signs and symptoms of dry eye disease and has been well tolerated. In addition, a genetic biomarker has been identified that showed a more pronounced treatment effect with Licaminlimab in patients with a specific TNFR1 genotype. If approved, Licaminlimab has the potential to transform the treatment paradigm with a precision medicine approach. 

Licaminlimab is an investigational drug in a registrational trial and has not received regulatory approval for commercial use in any country. 

About Privosegtor 

Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improvements in visual function, corroborated by anatomical preservation of the retina, including GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis and multiple sclerosis, where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility in the multiple sclerosis model. 

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Priority Medicines (PRIME) designation from the European Medicines Agency, as well as Orphan Drug designation from both agencies for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy. 

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country. 

About Oculis 

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis and non-arteritic anterior ischemic optic neuropathy. Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial and is being developed with a genotype-based approach for treating patients with dry eye disease. Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. 

For more information, please visit: www.oculis.com 

Contacts 

Oculis Contact 
Ms. Sylvia Cheung, CFO 
sylvia.cheung@oculis.com 

Investor Relations 
LifeSci Advisors 
Corey Davis, Ph.D. 
cdavis@lifesciadvisors.com 

Media Relations 
ICR Healthcare 
Amber Fennell / David Daley / Sean Leous 
oculis@icrhealthcare.com 

Cautionary Statement Regarding Forward-Looking Statements 

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotective therapy for optic neuritis and other neuro-ophthalmic and neuro-axonal diseases and the potential for Licaminlimab to transform the treatment paradigm in dry eye disease with a precision medicine approach; the initiation, enrollment, timing, progress and results of current and future clinical trials; Oculis’ research and development programs, regulatory and business strategy; Oculis’ future development plans; the timing or likelihood of regulatory filings and approvals; and statements about market opportunity, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and subject to risks, variability and contingencies, many of which are beyond Oculis’ control. Results from prior clinical trials may not be replicated in later clinical trials. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those expected and/or expressed or implied by such forward-looking statements, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. 

Elis announces the results of the conversion and exchange period
for its 2029 OCEANEs

Puteaux, October 7, 2026 – Elis (the “Company”) announces the results of the conversion/exchange period for its €380,000,000 2.25% bonds convertible into new shares and/or exchangeable for existing shares due September 22, 2029 (ISIN FR001400AFJ9) (the “Bonds”).

On September 11, 2026, the Company announced its decision to redeem all outstanding Bonds on October 13, 2026, pursuant to the first paragraph of Condition 1.10.1.3, “Early redemption at the Company’s option”, of the terms and conditions of the Bonds dated September 22, 2022 (the “Terms and Conditions”).

Capitalised terms that are not otherwise defined in this notice shall have the meanings given to them in the Terms and Conditions.

Bondholders had until October 2, 2026, to validly exercise their Conversion/Exchange Rights in accordance with the Terms and Conditions, at a conversion/exchange ratio of 6,256.8564 Elis shares per Bond.

A total of 3,767 Bonds were validly presented for conversion/exchange, representing 99.13% of the 3,800 Bonds outstanding on September 11, 2026. With a par value of €100,000 per Bond, this represents an aggregate nominal amount of €376,700,000.

Applying the Conversion/Exchange Ratio and the rounding provisions of the Terms and Conditions, these exercises will result in the delivery of a total of 23,569,556 Elis shares (ISIN FR0012435121), comprising 18,104,556 existing shares held in treasury and 5,465,000 new shares, representing in aggregate 9.89% of Elis’s share capital following the issuance of the new shares. The share capital of the Company now amounts to EUR 238,313,588, comprising 238,313,588 ordinary shares with a nominal value of EUR 1.00 each. The Company will use existing shares held following the completion of its share buyback program on July 9, 2026, thereby limiting the number of new shares to be issued. Settlement and delivery of the shares will be completed on October 7, 2026.

The remaining 33 Bonds, in respect of which conversion/exchange rights were not validly exercised, will be redeemed in cash on October 13, 2026, at a price of €100,129.45 per Bond, including €129.45 of accrued interest, representing an aggregate redemption amount of €3,304,271.85.

IMPORTANT NOTICE

This press release does not constitute an offer to sell, a solicitation of an offer to purchase, or an offer to purchase any securities of Elis in any jurisdiction.

Contacts

Nicolas Buron
Director of Investor Relations, Financing & Treasury
Phone: + 33 (0)1 75 49 98 30 – nicolas.buron@elis.com

Charline Lefaucheux
Investor Relations
Phone: + 33 (0)1 75 49 98 15 – charline.lefaucheux@elis.com

Attachment

• Elis announces the results of the conversion and exchange period for its 2029 OCEANEs

First patient enrolled in cohort combining bexobrutideg with venetoclax

Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL

Strategy includes evaluation of bexobrutideg given in combination with venetoclax and selected antibodies in the Roche portfolio of B-cell malignancy therapies

BRISBANE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the first patient has been enrolled in the Phase 1b/2 NX-5948-203 study evaluating bexobrutideg, an investigational oral Bruton’s tyrosine kinase (BTK) degrader, in combination with venetoclax, a standard-of-care therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

The study is being conducted under the global collaboration between Nurix and Roche and is designed to evaluate the safety, tolerability and clinical activity of bexobrutideg in combination with venetoclax, a BCL2 inhibitor. Data from the trial are expected to inform future registrational development strategies across lines of therapy in CLL, including evaluating bexobrutideg in combination with the anti-CD20 antibodies rituximab and obinutuzumab across multiple cohorts of patients with relapsed or refractory and previously untreated CLL, and potential expansion into other B-cell malignancies.

“The initiation of this study marks another important milestone in our effort to realize the full potential of bexobrutideg across B-cell malignancies,” said Arthur T. Sands, M.D., Ph.D., chief executive officer of Nurix. “Combination therapies are becoming increasingly important in the treatment of CLL, especially in earlier lines of therapy, and we believe bexobrutideg’s differentiated mechanism of action, robust single-agent activity and favorable tolerability make it an attractive partner for combination approaches to deliver deep, durable responses with fixed-duration therapy.”

About Bexobrutideg (NX-5948)
Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule degrader of Bruton’s tyrosine kinase (BTK) being developed by Nurix and Roche as a potential best-in-class therapy across oncology, immunology and neurology.

​​​Bexobrutideg is currently being evaluated in a broad clinical development program in patients with chronic lymphocytic leukemia (CLL), including the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study in patients with relapsed/refractory CLL previously treated with covalent and noncovalent BTKi and a BCL2i; the DAYBreak CLL-306 clinical trial (NCT07516093), a randomized Phase 3 trial comparing bexobrutideg to pirtobrutinib in patients with relapsed/refractory CLL previously treated with a covalent BTKi; the NX-5948-203 Phase 1b/2 clinical trial (NCT07520006), assessing the combination of bexobrutideg with venetoclax in patients with relapsed/refractory CLL and potentially treatment-naïve CLL; and the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) in patients with relapsed/refractory B-cell malignancies. Additional information about these clinical trials can be found at clinicaltrials.gov.

About Nurix Therapeutics
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical-stage oncology pipeline includes bexobrutideg, a degrader of BTK being co-developed with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix’s autoimmune disease pipeline includes bexobrutideg in collaboration with Roche and clinical-stage degraders of IRAK4 in collaboration with Gilead and STAT6 in collaboration with Sanofi. Nurix is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates in its wholly owned preclinical pipeline and under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information, visit www.nurixtx.com.

Forward-Looking Statements
This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding Nurix’s plans for the development of bexobrutideg and the potential of bexobrutideg to serve as a foundational component of future combination regimens. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) whether Nurix and Roche will be able to successfully conduct and complete clinical development of bexobrutideg pursuant to the Nurix-Roche collaboration; (ii) the unexpected emergence of adverse events or other undesirable side effects during clinical development; (iii) whether Nurix will have adequate resources to fund its obligations under the Nurix-Roche collaboration; (iv) whether the parties will be able to successfully co-commercialize bexobrutideg in the United States; and (v) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal period ended May 31, 2026, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.

Contacts:
Media & Investors
Kris Fortner
Nurix Therapeutics, Inc.
kfortner@nurixtx.com

SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “notes”). The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The shares of common stock, pre-funded warrants and notes to be sold in the offerings are being offered by Vaxcyte. Vaxcyte has granted the underwriters of the common stock and pre-funded warrant offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price per share, and has granted the underwriters of the note offering a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes at the public offering price, solely to cover over-allotments, in each case less underwriting discounts and commissions.

The aggregate gross proceeds to Vaxcyte from the common stock and pre-funded warrants offering are expected to be approximately $500 million and the aggregate gross proceeds to Vaxcyte from the notes offering are expected to be $500 million, in each case before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants and assuming no exercise of the underwriters’ options.

Vaxcyte intends to use the net proceeds from the offerings to fund (i) clinical development of the VAX-31 adult and pediatric programs, including (a) for the ongoing VAX-31 adult Phase 3 program, the trial evaluating concomitant administration with a seasonal influenza vaccine (OPUS-2, enrolled), the trial in adults who have previously received a pneumococcal vaccine (OPUS-3, enrolled) and the planned manufacturing consistency study, and the anticipated topline safety, tolerability and immunogenicity data announcements from such studies, and (b) for the VAX-31 infant Phase 2 dose-finding study (enrolled), the anticipated topline data announcement(s) from the primary three-dose immunization series and booster dose; (ii) manufacturing scale-up, processes and supply to support our clinical studies and the potential commercial launches of our PCV programs, including (a) to establish additional manufacturing capacity to meet potential incremental supply requirements for the global adult and pediatric populations following the potential initial commercial launch of VAX-31 in adults in the United States and (b) to build inventory levels in advance of such potential commercial launch; (iii) medical affairs, commercial and systems-related investments to prepare for and execute the anticipated U.S. launch of VAX-31 in adults; (iv) ongoing research and development of our other early-stage pipeline vaccine candidates; and (v) general corporate purposes, including working capital, operating expenses and capital expenditures, as well as potential expansion of Vaxcyte’s research pipeline.

The completion of the common stock and pre-funded warrant offering is not contingent on the completion of the note offering, and the completion of the note offering is not contingent on the completion of the common stock and pre-funded warrant offering.

The offerings are expected to close on October 9, 2026, subject to the satisfaction of customary closing conditions.

Jefferies, Leerink Partners, BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC and Guggenheim Securities are acting as joint book-running managers for the common stock and pre-funded warrant offering. Mizuho is acting as bookrunner and BTIG is acting as lead manager for the common stock and pre-funded warrant offering.

Jefferies, Leerink Partners, BofA Securities, Goldman Sachs & Co. LLC and Evercore ISI are acting as joint book-running managers for the note offering. Guggenheim Securities and Mizuho are acting as bookrunners and Needham & Company is acting as lead manager for the note offering.

J. Wood Capital Advisors is acting as financial advisor to Vaxcyte in connection with the note offering.

The notes will be senior, unsecured obligations of Vaxcyte and will accrue interest at a rate of 1.50% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, beginning on April 15, 2027. The notes will mature on October 15, 2032, unless earlier repurchased, redeemed or converted. Before July 15, 2032, noteholders will have the right to convert their notes only upon the occurrence of certain events. From and after July 15, 2032, noteholders may convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Vaxcyte will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Vaxcyte’s election. The initial conversion rate is 11.1607 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $89.60 per share of common stock. The initial conversion price represents a premium of approximately 40.0% over the public offering price per share of common stock in the common stock offering. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Vaxcyte’s option at any time, and from time to time, on or after October 22, 2029 and on or before the 20th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Vaxcyte’s common stock exceeds 130% of the conversion price for a specified period of time. The notes will also be redeemable, in whole and not in part, for cash at Vaxcyte’s election at any time if the principal amount of the notes then outstanding is less than 10% of the aggregate principal amount of the notes issued in this offering (including any additional notes issued pursuant to any exercise of the underwriters’ option to purchase additional notes). The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

If a “fundamental change” (as defined in the indenture for the notes) occurs, then, subject to a limited exception, noteholders may require Vaxcyte to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.

A shelf registration statement relating to the offered securities was filed with the Securities and Exchange Commission (SEC) and was automatically effective upon filing on May 24, 2024. A preliminary prospectus supplement and accompanying prospectus relating to each offering has been filed, and a final prospectus supplement and accompanying prospectus relating to each offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to each offering may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by email at syndicate@leerink.com or by phone at (800) 808-7525, ext. 6105.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Vaxcyte

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, has generated positive Phase 2 clinical results in both adults and infants and is designed to cover more serotypes than any PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages Vaxcyte’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in Vaxcyte’s PCV franchise.

VAX-A1 is a prophylactic vaccine candidate designed to provide broad, strain-independent protection against disease caused by Group A Strep and is currently being evaluated in a Phase 1 clinical study in adults. Group A Strep remains a significant global cause of morbidity and mortality across both adult and pediatric populations and is a leading driver of antibiotic use, underscoring the substantial public health burden.

Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, Vaxcyte’s system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-GI, a vaccine candidate designed to prevent Shigella.

Forward-Looking Statements

This press release contains forward-looking statements regarding Vaxcyte, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the completion, timing and expected closing of the offerings, the expected amount of the gross proceeds of the offerings and the intended use of the net proceeds therefrom. Words such as “expects,” “intends,” “intended,” “designed,” “aim,” “will” and “may” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements represent Vaxcyte’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market and other conditions, the satisfaction of the closing conditions related to the offerings, risks described under the caption “Risk Factors” in the preliminary prospectus supplements (and, when available, the final prospectus supplements) for the offerings, risks relating to Vaxcyte’s business, and the other risks described more fully in Vaxcyte’s filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. Vaxcyte may not consummate the offerings described in this press release and, if the offerings are consummated, cannot provide any assurances regarding its ability to effectively apply the net proceeds as described above. You should not place undue reliance on these forward-looking statements. The forward-looking statements included in this press release speak only as of the date of this press release, and Vaxcyte does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law.

Contacts:

Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com

Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
investors@vaxcyte.com

Digital Realty’s Osaka campus expands with commencement of construction on a new 24 MW facility designed for high-density computing and advanced cooling

SINGAPORE, Oct. 07, 2026 (GLOBE NEWSWIRE) — Digital Realty (NYSE: DLR), the world’s largest cloud- and carrier-neutral data center platform, today announced the commencement of construction of KIX15, a new 24 megawatt (MW) data center at its KIX Campus in Ibaraki City, Osaka Prefecture, Japan.

Developed by MC Digital Realty (MCDR), Digital Realty’s 50/50 joint venture in Japan with Mitsubishi Corporation, KIX15 will be the fifth data center at the KIX Campus and is scheduled to commence operations in the fourth quarter of 2028. The new facility is planned to further expand Digital Realty’s presence across the Tokyo and Osaka metropolitan areas. Upon completion, KIX15 will bring MCDR’s Japan portfolio to 10 data centers, representing approximately 220 MW of aggregate IT capacity.

This expansion follows the opening of the NRT14 Data Center in Inzai City, Chiba Prefecture, earlier this year. NRT14 is one of the first facilities in Japan to achieve the DGX-Ready Data Center certification.

KIX15 will be part of PlatformDIGITAL^®, Digital Realty’s global data center platform spanning 300+ data centers across 55+ metros in 30+ countries on six continents.

Serene Nah, Managing Director and Head of Asia Pacific, Digital Realty, said, “Japan is a strategic market for Digital Realty and a key part of our long-term growth in Asia Pacific. Our continued investment in Japan reflects both our confidence in the market and our commitment to building the infrastructure customers will need for the long term.

“KIX15 is the next step in that commitment. As customer requirements become more distributed and complex, the combination of local scale and global reach will become increasingly important.”

Advancing AI Infrastructure in Kansai

KIX15 is a key component of MCDR’s Kansai AI Infrastructure Co-Creation Project, an initiative centered on the KIX Campus to support the development of AI infrastructure across the Kansai region.

The project brings together the expansion of the KIX Campus with stronger domestic and international connectivity and deeper collaboration with telecommunications and technology partners.

Kohei Yamashita, Representative Director and Chief Executive Officer of MC Digital Realty, said, “Kansai has a growing opportunity to play a larger role in Japan’s AI economy. Realizing that potential will require an ecosystem that can support businesses as they build and scale AI, bringing together computing infrastructure, connectivity and technology expertise.”

As adoption of generative AI and cloud services grows, demand is increasing for higher-density computing environments, advanced cooling and reliable connectivity in Japan. KIX15 is designed to support hybrid air- and liquid-cooling technologies. Designed to provide a high level of security and campus-based scalability, the facility is expected to support a broad range of customers, including hyperscalers, cloud service providers and companies deploying AI infrastructure.

Through Digital Realty’s ServiceFabric^® orchestration and interconnection platform and collaboration with multiple network service providers, customers will have access to low-latency connectivity to key locations and cloud services in Japan and more than 300 Digital Realty data centers worldwide. This enables customers to expand into high-power, high-density infrastructure at the KIX Campus while maintaining connectivity with their existing IT environments.

About Digital Realty
Digital Realty brings companies and data together by delivering the full spectrum of data center, colocation, and interconnection solutions. PlatformDIGITAL^®, the company’s global data center platform, provides customers with a secure data meeting place and a proven Pervasive Datacenter Architecture (PDx^®) solution methodology for powering innovation, from cloud and digital transformation to emerging technologies like artificial intelligence (AI), and efficiently managing Data Gravity challenges. Digital Realty gives its customers access to the connected data communities that matter to them with a global data center footprint of 300+ facilities in 55+ metros across 30+ countries on six continents. To learn more about Digital Realty, please visit digitalrealty.com or follow us on LinkedIn and X.

About MC Digital Realty
MC Digital Realty, Inc., established in September 2017, is a 50/50 joint venture between Mitsubishi Corporation and Digital Realty. The company provides the full spectrum of data center services in Japan, including colocation and interconnection solutions, by leveraging Mitsubishi Corporation’s real estate and infrastructure investment expertise and customer network, as well as Digital Realty’s global data center platform, PlatformDIGITAL^®.

For Additional Information

Media Contacts
Joyce Ng
Digital Realty
jong@digitalrealty.com

Investor Relations
Jordan Sadler / Jim Huseby
Digital Realty
+1 (737) 281-0101
InvestorRelations@digitalrealty.com

Safe Harbor Statement
This press release contains forward-looking statements which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially, including statements related to the Asian markets, the company’s development plans, expected completion dates, expected growth in digital transformation and demand, customer demand and the company’s strategy. For a list and description of risks and uncertainties, see the reports and other filings by the company with the U.S. Securities and Exchange Commission. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ab8f4779-e20a-4c84-8555-2c9d13184fbb

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) — Figure Technology Solutions, Inc. (Nasdaq: FIGR; OPEN: FGRS) (“Figure”), the leading blockchain-native capital marketplace for the origination, funding, sale, and trading of tokenized assets, today reported select unaudited preliminary operating data for the month and quarter ended September 30, 2026 that was at the high end of the Company’s previously issued guidance range of $4.8B – $5.2B.

Consumer Loan Marketplace Volume as presented in this release for September and Q3 2026 excludes volume originated on the Kiavi platform following the September 1, 2026 closing (“Merger”). The Company’s previously issued Q3 2026 guidance did not include the contribution of Kiavi. Kiavi loan volumes for the approximate one-month period post Merger will be included with Figure’s Q3 2026 financial results, to be released in November.

Dollars in Millions	September 2026		August 2026		M/M Change		September 2025		Y/Y Change
Consumer Loan Marketplace Volume1	$	1,783	$	1,640	9	%	$	876	104	%
$YLDS In Circulation2	$	504	$	446	13	%	$	21	n.m.
Democratized Prime3
Matched Offers Balance	$	588	$	583	1	%	$	22	n.m.
Borrower Demand	$	600	$	590	2	%	$	27	n.m.
Available Lender Supply	$	825	$	829	-1	%	$	26	n.m.

Dollars in Millions	Q3 2026		Q2 2026		Q/Q Change		Q3 2025		Y/Y Change
Consumer Loan Marketplace Volume1	$	5,119	$	4,259	20	%	$	2,469	107	%
$YLDS In Circulation2	$	504	$	556	-9	%	$	21	n.m.
Democratized Prime3
Matched Offers Balance	$	588	$	392	50	%	$	22	n.m.
Borrower Demand	$	600	$	414	45	%	$	27	n.m.
Available Lender Supply	$	825	$	522	58	%	$	26	n.m.

¹ Excludes volume originated on the Kiavi platform following the September 1, 2026 closing
² $YLDS launched in February 2025
³ Democratized Prime launched in June 2025

About Certain Operating Metrics

In order to better help understand our financial performance, we use several operating metrics, some of which are discussed below, to evaluate our business and results, measure performance, identify trends, formulate plans, and make strategic decisions. Our determination and presentation of these metrics may differ from that of other companies. The presentation of these metrics is meant to be considered in addition to, not as a substitute for or in isolation from, our financial measures prepared in accordance with GAAP.

Consumer Loan Marketplace Volume: We define Consumer Loan Marketplace Volume as the total U.S. dollar equivalent value of originations of HELOCs, DSCRs, and personal loans on our LOS, as well as the volume of third-party loans traded on Figure Connect. We believe this measure is an indication of our scale and represents the potential revenue opportunity from the technology used for consumer credit loan originations. This measure does not include the contribution from Figure’s recently closed transaction with Kiavi. Prior-period volumes will be recast following our next quarterly earnings release.

$YLDS in Circulation: We define $YLDS in Circulation as the total U.S. dollar equivalent value of unsecured face-amount certificates solely backed by the assets of Figure Certificate Company (FCC), which is the issuer of the certificates. This is reported as an end of period outstanding balance.

Matched Offers: We define Matched Offers as the U.S. dollar equivalent value of offers matched between borrowers and lenders on the Democratized Prime platform. This is reported as an end of period outstanding balance.

Borrower Demand: We define Borrower Demand as the U.S. dollar equivalent value that borrowers seek to borrow from the lending pool on the Democratized Prime platform. This is reported as an end of period outstanding balance.

Available Lender Supply: We define Lender Supply as the U.S. dollar equivalent value that lenders have made available in the lending pool on the Democratized Prime platform. This is reported as an end of period outstanding balance.

Financial Disclosure Advisory

The information in this release is unaudited and the information for the months in the most recent fiscal quarter is preliminary, based on Figure’s estimates, and subject to completion of financial closing procedures. Final results for the most recent fiscal quarter, as reported in Figure’s quarterly and annual filings with the U.S. Securities and Exchange Commission (“SEC”), might vary from the information in this release. Figure may at times make revisions to prior estimates to ensure consistency across comparable periods.

Forward Looking Statements Disclaimer

This press release contains forward-looking statements intended to be covered by the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release, including without limitation statements regarding our future financial performance, including our expectations regarding our operating data, guidance, the expected reconciliation of Kiavi’s contribution, and the recasting of prior-period volumes, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms, and similar expressions. Forward-looking statements are predictions based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These statements speak only as of the date of this press release.

Important factors that could cause actual results to differ materially include, among others: the ability of the Company to successfully integrate the business and operations of Kiavi; the ability to realize the anticipated benefits and synergies of the Merger; potential adverse effects on the Company’s business, financial condition and results of operations resulting from the Merger;  regulatory matters, including compliance with applicable laws and regulations; our history of losses and the risk that we may not maintain profitability; our reliance on HELOCs and exposure to fluctuations in the HELOC market and housing values; our ability to attract and retain borrowers, partners, and loan purchasers and to drive adoption of Figure-branded and Partner-branded channels including Figure Connect; loan performance and default rates and the effect of credit performance on access to and pricing of warehouse facilities, whole-loan sales, and securitizations; changes in interest rates and U.S. monetary policy that impact originations, funding costs, and investor demand; legal and regulatory risks affecting lending and mortgage-related activities and the evolving framework for digital assets, including potential changes in the characterization or regulation of certain digital assets and related products; dependence on key third-party providers including cloud, custodial, valuation, and data vendors and risks from outages or service disruptions; technology failures, cybersecurity incidents, or other operational disruptions; protection and enforcement of intellectual property; compliance with licensing, consumer protection, privacy, data security, and sanctions/AML laws, and shifting enforcement priorities at the federal and state levels; our ability to remediate previously identified material weaknesses and meet our public company reporting and internal control obligations; competition; macroeconomic and geopolitical conditions; our dual-class structure and concentrated voting control and related impacts on corporate governance; equity market volatility affecting our Class A common stock; and the other risks described in “Risk Factors” in our Annual Report on Form 10-K for the period ended December 31, 2025, filed with the SEC on March 16, 2026, our Quarterly Report on Form 10-Q for the three months ended June 30, 2026, filed with the SEC on August 14, 2026, and in our other filings with the SEC.

About Figure Technology Solutions, Inc

Figure is a blockchain-native capital marketplace that seamlessly connects origination, funding, and secondary market activity. More than 489 partners use its loan origination system and capital marketplace. Collectively, Figure and its partners have originated approximately $30 billion of home equity to date, among other products, making Figure’s ecosystem the largest non-bank provider of HELOCs. The fastest growing components are Figure Connect, its consumer credit marketplace, and Democratized Prime, Figure’s on-chain lend-borrow marketplace. Figure’s ecosystem also includes DART (Digital Asset Registry Technology) for asset custody and lien perfection, and $YLDS, an SEC-registered yield-bearing stablecoin that operates as a tokenized money market fund.

Figure is the market leader in real world asset (RWA) tokenization. The company has received AAA ratings from S&P and Moody’s on multiple loan securitizations, the first of its kind for blockchain finance. For more information, visit https://figure.com or follow Figure on LinkedIn.

News & Information Disclosure

Investors should note we may use our website (https://www.figure.com/), our investor relations website (https://investors.figure.com/), our operating metrics website (https://figure.com/investors/metrics) and the social media accounts of Figure, Figure Markets and/or Mike Cagney, our Co-Founder and Executive Chairman, as a means of disclosing information and for complying with our disclosure obligations under Regulation FD.  These include X (@figure, @mcagney, @figuremarkets), LinkedIn (https://www.linkedin.com/company/figuretechnologies/, https://www.linkedin.com/in/mikecagney/), Instagram (@figuretechnologies), Facebook (https://www.facebook.com/Figure/), and YouTube (@figuretechnologies).  The information we post through these channels may be deemed material. Investors should monitor these channels in addition to reviewing our press releases, SEC filings, and public conference calls.

Investor Contact: investors@figure.com

GUADALAJARA, Mexico, Oct. 06, 2026 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger traffic figures for September 2026, compared with September 2025.

During September 2026, GAP’s 12 Mexican airports recorded a 6.7% decrease in total passenger traffic compared to the same period of the previous year. Tijuana, Puerto Vallarta and Los Cabos airports recorded decreases of 12.1%, 10.4% and 7.5%, respectively.

The passenger traffic decrease during September was mainly due to a decline in seat capacity offered by the airlines, particularly in the domestic market. During the final days of the month, adverse weather conditions associated with Hurricane Polo affected the Mexican Pacific region and Baja California Sur, partially affected operations at Puerto Vallarta and Los Cabos airports. In the domestic market, the main routes that recorded declines were Puerto Vallarta–Tijuana, Puerto Vallarta–Monterrey, Los Cabos–Guadalajara, and Tijuana–Guadalajara. In the international market, the largest declines were recorded on routes from Los Cabos to Dallas-Fort Worth, Los Angeles and Phoenix, as well as on routes from Puerto Vallarta to San Francisco and Phoenix.

In Jamaica, passenger traffic at Montego Bay Airport decreased by 16.6%, while passenger traffic at Kingston Airport decreased by 3.8%, both compared to September 2025.

Domestic Terminal Passengers (in thousands):
Airport	Sep-25	Sep-26	% Change	Jan – Sep 25	Jan – Sep 26	% Change
Guadalajara	990.3	935.4	(5.6%)	9,295.2	9,583.0	3.1%
Tijuana*	675.4	559.4	(17.2%)	6,434.0	6,087.8	(5.4%)
Los Cabos	208.4	206.9	(0.7%)	2,170.7	2,145.5	(1.2%)
Puerto Vallarta	235.2	212.7	(9.6%)	2,354.6	2,267.6	(3.7%)
Montego Bay	0.0	0.0	0.0%	0.0	0.0	0.0%
Guanajuato	180.6	158.4	(12.3%)	1,668.3	1,617.9	(3.0%)
Hermosillo	164.3	153.8	(6.4%)	1,591.3	1,494.6	(6.1%)
Kingston	0.3	0.3	1.8%	1.0	1.3	27.9%
Morelia	61.1	46.9	(23.2%)	567.7	556.3	(2.0%)
La Paz	99.1	93.5	(5.6%)	955.9	1,044.1	9.2%
Mexicali	94.6	71.8	(24.1%)	929.2	808.4	(13.0%)
Aguascalientes	49.4	53.9	9.2%	483.2	487.7	0.9%
Los Mochis	53.7	48.6	(9.4%)	522.9	516.7	(1.2%)
Manzanillo	8.6	10.5	21.7%	97.6	98.6	1.0%
Total	2,821.1	2,552.1	(9.5%)	27,071.6	26,709.5	(1.3%)

International Terminal Passengers (in thousands):
Airport	Sep-25	Sep-26	% Change	Jan – Sep 25	Jan – Sep 26	% Change
Guadalajara	421.9	463.9	10.0%	4,396.2	4,689.8	6.7%
Tijuana*	268.7	270.7	0.8%	3,041.2	2,896.8	(4.7%)
Los Cabos	197.0	168.0	(14.7%)	3,500.5	3,205.7	(8.4%)
Puerto Vallarta	107.4	94.5	(12.0%)	2,819.9	2,272.6	(19.4%)
Montego Bay	285.6	238.3	(16.6%)	3,847.2	2,866.9	(25.5%)
Guanajuato	68.9	71.7	4.1%	782.1	741.2	(5.2%)
Hermosillo	6.0	6.6	10.1%	59.3	64.4	8.6%
Kingston	137.3	132.1	(3.8%)	1,409.7	1,384.8	(1.8%)
Morelia	55.8	52.3	(6.3%)	525.7	604.2	14.9%
La Paz	2.4	2.6	9.9%	25.5	34.0	33.5%
Mexicali	0.6	0.6	2.6%	5.5	5.8	4.0%
Aguascalientes	26.4	25.8	(2.5%)	245.7	248.1	1.0%
Los Mochis	0.6	0.7	19.3%	6.1	6.7	11.5%
Manzanillo	2.5	2.2	(12.4%)	72.4	62.1	(14.2%)
Total	1,581.0	1,529.8	(3.2%)	20,736.9	19,083.0	(8.0%)

Total Terminal Passengers (in thousands):
Airport	Sep-25	Sep-26	% Change	Jan – Sep 25	Jan – Sep 26	% Change
Guadalajara	1,412.2	1,399.3	(0.9%)	13,691.4	14,272.9	4.2%
Tijuana*	944.1	830.1	(12.1%)	9,475.2	8,984.6	(5.2%)
Los Cabos	405.5	374.9	(7.5%)	5,671.1	5,351.2	(5.6%)
Puerto Vallarta	342.6	307.1	(10.4%)	5,174.5	4,540.2	(12.3%)
Montego Bay	285.7	238.3	(16.6%)	3,847.2	2,866.9	(25.5%)
Guanajuato	249.4	230.1	(7.7%)	2,450.4	2,359.1	(3.7%)
Hermosillo	170.3	160.3	(5.8%)	1,650.5	1,559.0	(5.5%)
Kingston	137.6	132.4	(3.8%)	1,410.7	1,386.0	(1.8%)
Morelia	116.9	99.2	(15.1%)	1,093.4	1,160.5	6.1%
La Paz	101.5	96.1	(5.3%)	981.4	1,078.2	9.9%
Mexicali	95.1	72.4	(23.9%)	934.7	814.1	(12.9%)
Aguascalientes	75.8	79.7	5.1%	728.9	735.8	1.0%
Los Mochis	54.3	49.3	(9.1%)	529.0	523.5	(1.0%)
Manzanillo	11.1	12.7	14.0%	170.0	160.7	(5.4%)
Total	4,402.0	4,081.9	(7.3%)	47,808.5	45,792.6	(4.2%)

*Passengers in Tijuana who use CBX in both directions are classified as international.

CBX users (in thousands):
Airport	Sep-25	Sep-26	% Change	Jan – Sep 25	Jan – Sep 26	% Change
Tijuana	262.7	266.2	1.4%	2,984.0	2,856.4	(4.3%)

Highlights for the month:

• Seats and load factors
  The seats available during September 2026 decreased by 7.2%, compared to September 2025. The load factors for the month went from 80.7% in September 2025 to 81.0% in September 2026.

Company Description

Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexico’s Pacific region, including the major cities of Guadalajara and Tijuana, the four tourist destinations of Puerto Vallarta, Los Cabos, La Paz and Manzanillo, and six other mid-sized cities: Hermosillo, Guanajuato, Morelia, Aguascalientes, Mexicali, and Los Mochis. In February 2006, GAP’s shares were listed on the New York Stock Exchange under the ticker symbol “PAC” and on the Mexican Stock Exchange under the ticker symbol “GAP”. In April 2015, GAP acquired 100% of Desarrollo de Concesiones Aeroportuarias, S.L., which owns a majority stake in MBJ Airports Limited, a company operating Sangster International Airport in Montego Bay, Jamaica. In October 2018, GAP entered into a concession agreement for the Norman Manley International Airport operation in Kingston, Jamaica, and took control of the operation in October 2019.

This press release may contain forward-looking statements. These statements are statements that are not historical facts and are based on management’s current view and estimates of future economic circumstances, industry conditions, company performance, and financial results. The words “anticipates”, “believes”, “estimates”, “expects”, “plans” and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations, and the factors or trends affecting financial condition, liquidity, or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends, or results will occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.

In accordance with Section 806 of the Sarbanes-Oxley Act of 2002 and Article 42 of the “Ley del Mercado de Valores”, GAP has implemented a “whistleblower” program, which allows complainants to anonymously and confidentially report suspected activities that involve criminal conduct or violations. The telephone number in Mexico, facilitated by a third party responsible for collecting these complaints, is 800 04 ETICA (38422) or WhatsApp +52 55 6538 5504. The website is www.lineadedenunciagap.com or by email at denuncia@lineadedenunciagap.com. GAP’s Audit Committee will be notified of all complaints for immediate investigation.

Saúl Villarreal, Chief Financial Officer	svillarreal@aeropuertosgap.com.mx
Gisela Murillo, Investor Relations	gmurillo@aeropuertosgap.com.mx +52 33 3880 1100 ext. 20294

AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — Digital Realty (NYSE: DLR), the world’s largest cloud- and carrier-neutral data center platform, announced today that Digital Euro Finco, LLC, a wholly owned indirect finance subsidiary of the company’s operating partnership, Digital Realty Trust, L.P., priced an offering of €1 billion aggregate principal amount of 5.125% Guaranteed Notes due 2036 at a price of 99.289% of the principal amount (the “Euro Notes”).

The Euro Notes will be senior unsecured obligations of Digital Euro Finco, LLC and will be fully and unconditionally guaranteed by the company and the operating partnership. Interest on the Euro Notes will be payable annually in arrears at a rate of 5.125% per annum from and including October 9, 2026 and will mature on October 9, 2036. Closing of the offering is expected to occur on October 9, 2026, subject to the satisfaction of customary closing conditions.

The company intends to allocate an amount equal to the net proceeds from the offering of the Euro Notes to finance or refinance, in part or in full, new and/or existing projects consistent with Digital Realty’s Green Bond Framework, including the development and redevelopment of such projects. Pending the allocation of the net proceeds of the Euro Notes to such projects, all or a portion of an amount equal to the net proceeds from the Euro Notes may be used to temporarily repay borrowings outstanding under the operating partnership’s global revolving credit facilities, acquire additional properties or businesses, fund development opportunities, invest in interest-bearing accounts and short-term, interest-bearing securities which are consistent with the company’s intention to qualify as a REIT for U.S. federal income tax purposes, and to provide for working capital and other general corporate purposes, including potentially for the repayment of other debt, or the redemption, repurchase, repayment or retirement of outstanding equity or debt securities, or a combination of the foregoing.

The Euro Notes are being sold only outside the United States in reliance on Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”). The Euro Notes have not been and will not be registered under the Securities Act and may not be offered or sold in the United States or to United States persons (within the meaning of Regulation S under the Securities Act) absent registration or an applicable exemption from registration requirements. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the Euro Notes, nor shall there be any offer, solicitation or sale of the Euro Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Safe Harbor Statement

This press release contains forward-looking statements which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially, including statements related to the timing and consummation of the offering of the Euro Notes and the expected use of the net proceeds. The company can provide no assurances that it will be able to complete the offering on the anticipated terms, or at all. For a further list and description of such risks and uncertainties, see the company’s reports and other filings with the U.S. Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2025 and the Quarterly Report on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Reg S Statement

This communication is not an offer to sell or a solicitation of an offer to buy securities of Digital Realty Trust, Inc. or its subsidiaries. The securities have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction of the United States. Consequently, the securities may not be offered, sold, resold, transferred, delivered or distributed, directly or indirectly, into or within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. Any offering of the securities will be conducted pursuant to Regulation S under the Securities Act.

Notice to European Economic Area Retail Investors

The Euro Notes are not intended to be offered, sold or otherwise made available to and, with effect from such date, should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (the “EEA”). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, “MiFID II”); or (ii) a customer within the meaning of Directive 2016/97/EU (as amended, the “IMD”), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II. No key information document required by Regulation (EU) No 1286/2014 (as amended, the “PRIIPs Regulation”) for offering or selling any in scope instrument or otherwise making such instruments available to retail investors in the EEA has been prepared. Offering or selling the Euro Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation. This communication has been prepared on the basis that any offers or sales of Euro Notes in any Member State of the EEA will be made pursuant to an exemption under Regulation (EU) 2017/1129 (as amended or superseded, the “Prospectus Regulation”) from the requirement to publish a prospectus for offers or sales of Euro Notes. This communication is not a prospectus for the purposes of the Prospectus Regulation.

Notice to UK Retail Investors

This announcement is for distribution only to, and is directed at, persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Financial Promotion Order”), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “relevant persons”). This announcement is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.

The Euro Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the United Kingdom. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client, as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (“EUWA”); or (ii) a customer within the meaning of the provisions of the Financial Services and Markets Act 2000, as amended (the “FSMA”) and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97, where that customer would not qualify as a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA (“UK MiFIR”). Consequently, no key information document required by Regulation (EU) No 1286/2014 as it forms part of domestic law by virtue of the EUWA (the “UK PRIIPs Regulation”) for offering or selling the Euro Notes or otherwise making them available to retail investors in the United Kingdom has been prepared and therefore offering or selling the Euro Notes or otherwise making them available to any retail investor in the United Kingdom may be unlawful under the UK PRIIPs Regulation.

Relevant stabilization regulations including FCA/ICMA apply. Manufacturer target market (MIFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs or UK PRIIPs key information document (KID) has been prepared as not available to retail in EEA or UK.

Investor Relations
Jordan Sadler / Jim Huseby
Digital Realty
+1 (737) 281-0101
InvestorRelations@digitalrealty.com

Tórshavn, Faroe Islands, 2026-10-06 (GLOBE NEWSWIRE) — P/F Atlantic Petroleum (Nasdaq Copenhagen: ATLA DKK) has today, pursuant to Article 3f of the Company’s Articles of Association, entered into a convertible loan agreement in an aggregate principal amount of DKK 360,000 with one lender.

The principal terms of the convertible loan is as follows:

• The lender is entitled to convert the loan, including accrued interest, into shares in the Company.
• The conversion price has been fixed at DKK 5.16 per share.
• The lenders’ right to convert the loan into shares in the Company may be exercised during a 20-day period commencing in connection with publication of the Company’s annual or quarterly interim report.

Upon conversion of the loan into new shares, the new shares will be issued without pre-emptive rights for the Company’s existing shareholders and will carry the same rights as the Company’s existing shares. Application will be made for admission of the new shares to trading on Nasdaq Copenhagen in connection with their issuance.

The resolution regarding the issuance of the convertible loan will be incorporated into the Company’s Articles of Association. The updated Articles of Association will be made available on the Company’s website.

Further Details:

Further details can be obtained from Mark T. Højgaard, (markh@petroleum.fo). This announcement will be available, together with other information about Atlantic Petroleum, on the Company’s website: www.petroleum.fo.

Announcement no.16/2026

Issued 06-10-2026

P/F Atlantic Petroleum
P.O. Box 1228
FO-110 Tórshavn
Faroe Islands

Website: www.petroleum.fo

 Not for distribution to U.S. newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, into the United States

Vancouver, BC, Oct. 06, 2026 (GLOBE NEWSWIRE) — Terra Clean Energy Corp. (“Terra Clean Energy” or the “Company“) (CSE: TCEC) (OTCQB: TCEFF) (FSE: C9O0) is pleased to announce the successful closing of its previously announced upsized brokered private placement of units of the Company (the “Units”) for aggregate gross proceeds of approximately $1.97 million (the “Brokered Offering”). A portion of the private placement of Units also closed concurrently on a non-brokered basis for additional gross proceeds of $461,062 (the “Non-Brokered Offering” and together with the Brokered Offering, the “Offerings”).

The Offerings were led by Centurion One Capital Corp. as lead agent and sole bookrunner (the “Lead Agent”) in respect of the Brokered Offering and fiscal advisor in respect of the Non-Brokered Offering.

Greg Cameron, Chief Executive Officer of the Company commented: “We are very pleased to have successfully completed this oversubscribed financing. Centurion One Capital led the raise, served as an anchor investor, and brought together a strong group of long-term investors who share our confidence in Terra Clean Energy’s growth strategy. The proceeds will allow us to further advance the Marysvale Uranium Mines Project in Utah, while continuing to position the Company to benefit from the growing demand for secure domestic uranium supply.”

A total of 17,342,257 Units were sold under the Offerings at a price of $0.14 per Unit (the “Issue Price”) for aggregate gross proceeds of approximately $2,427,916. Each Unit consists of one common share in the capital of the Company (each, a “Share“) and one Share purchase warrant (each, a “Warrant“). The Shares and Warrants issued in connection with the Offerings are subject to a statutory hold period of four months and one day from the Closing Date in accordance with applicable Canadian securities legislation. Each Warrant shall entitle the holder thereof to purchase one Share at a price of $0.22 for a period of three (3) years from October 6, 2026 (the “Closing Date”).

The Warrants will be subject to an acceleration right (the “Warrant Acceleration Right“) if, on any fifteen (15) consecutive trading days, beginning on the Closing Date, the daily volume weighted average trading price of the Share is greater than $0.44. If the Company exercises its Warrant Acceleration Right, the new expiry date of the Warrants will be the 30th day following the notice of such exercise.

The net proceeds of the Offerings will be used for capital expenditures and general working capital purposes.

In connection with the Offerings, the Lead Agent received: (i) a cash commission of $194,233; and (ii) an aggregate of 1,387,380 broker warrants (the “Broker Warrants“), with each such Broker Warrant entitling the holder to acquire one Unit of the Company at any time for a period of three (3) years from the date of issuance of such Broker Warrant at an exercise price equal to the Issue Price. The Warrants underlying each Unit acquired upon exercise of a Broker Warrant shall be exercisable for a period of three (3) years from the date of issuance of the Broker Warrant.

Insiders of the Company (the “Insiders“) acquired an aggregate of 700,000 Units issued under the Offerings. Such Insider’s participation in the Offerings constitutes a “related party transaction”, as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“). A formal valuation was not required under MI 61-101 as the Company is not listed on any of the stock exchanges specified in MI 61-101. Minority shareholder approval was also not required as the fair market value of the consideration for the transaction involving the Insiders does not exceed 25% of the Company’s capitalization as of the date hereof.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“) or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Contact Information

Terra Clean Energy Corp.

Greg Cameron, Chief Executive Officer
416-277-6174
Email: info@tcec.energy

ABOUT TERRA CLEAN ENERGY CORP.

Terra Clean Energy Corp. is a Canadian-based uranium exploration and development company. The Company is currently developing the South Falcon East uranium project located in the Athabasca Basin region, Saskatchewan, Canada as well as past producing uranium mines in Utah and uranium exploration properties in Wyoming, United States. The Company’s strategy is to find and advance late stage uranium projects to support growing demand for Nuclear Power and secure domestic mineral supply chains.

For further information please visit Terra Clean Energy’s website at www.tcec.energy.

ABOUT CENTURION ONE CAPITAL CORP.

Centurion One Capital’s mission is to ignite the world’s most visionary entrepreneurs to conquer the greatest challenges of tomorrow, fueling their ambitions with transformative capital, unparalleled expertise, and a global network of influential connections. Every interaction is guided by our core values of respect, integrity, commitment, excellence in execution, and uncompromising performance. We make principal investments, drawing on the time-honored principles of merchant banking, where aligned incentives forge enduring partnerships. Centurion One Capital: A superior approach to investment banking.
The CSE has not reviewed nor accepts responsibility for the adequacy or accuracy of this release.

Statements in this release that are not historical facts are “forward-looking statements” and readers are cautioned that any such statements are not guarantees of future performance, and that actual developments or results, may vary materially from these “forward-looking statements”.